40
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Characterization of ferroptosis in murine models of hemochromatosis

      research-article

      Read this article at

          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Ferroptosis is a recently identified iron‐dependent form of nonapoptotic cell death implicated in brain, kidney, and heart pathology. However, the biological roles of iron and iron metabolism in ferroptosis remain poorly understood. Here, we studied the functional role of iron and iron metabolism in the pathogenesis of ferroptosis. We found that ferric citrate potently induces ferroptosis in murine primary hepatocytes and bone marrow–derived macrophages. Next, we screened for ferroptosis in mice fed a high‐iron diet and in mouse models of hereditary hemochromatosis with iron overload. We found that ferroptosis occurred in mice fed a high‐iron diet and in two knockout mouse lines that develop severe iron overload ( Hjv –/– and Smad4 Alb/Alb mice) but not in a third line that develops only mild iron overload ( Hfe –/– mice). Moreover, we found that iron overload–induced liver damage was rescued by the ferroptosis inhibitor ferrostatin‐1. To identify the genes involved in iron‐induced ferroptosis, we performed microarray analyses of iron‐treated bone marrow–derived macrophages. Interestingly, solute carrier family 7, member 11 ( Slc7a11), a known ferroptosis‐related gene, was significantly up‐regulated in iron‐treated cells compared with untreated cells. However, genetically deleting Slc7a11 expression was not sufficient to induce ferroptosis in mice. Next, we studied iron‐treated hepatocytes and bone marrow–derived macrophages isolated from Slc7a11 –/– mice fed a high‐iron diet. Conclusion: We found that iron treatment induced ferroptosis in Slc7a11 –/– cells, indicating that deleting Slc7a11 facilitates the onset of ferroptosis specifically under high‐iron conditions; these results provide compelling evidence that iron plays a key role in triggering Slc7a11‐mediated ferroptosis and suggest that ferroptosis may be a promising target for treating hemochromatosis‐related tissue damage. (H epatology 2017;66:449–465).

          Related collections

          Most cited references31

          • Record: found
          • Abstract: found
          • Article: not found

          ACSL4 dictates ferroptosis sensitivity by shaping cellular lipid composition.

          Ferroptosis is a form of regulated necrotic cell death controlled by glutathione peroxidase 4 (GPX4). At present, mechanisms that could predict sensitivity and/or resistance and that may be exploited to modulate ferroptosis are needed. We applied two independent approaches-a genome-wide CRISPR-based genetic screen and microarray analysis of ferroptosis-resistant cell lines-to uncover acyl-CoA synthetase long-chain family member 4 (ACSL4) as an essential component for ferroptosis execution. Specifically, Gpx4-Acsl4 double-knockout cells showed marked resistance to ferroptosis. Mechanistically, ACSL4 enriched cellular membranes with long polyunsaturated ω6 fatty acids. Moreover, ACSL4 was preferentially expressed in a panel of basal-like breast cancer cell lines and predicted their sensitivity to ferroptosis. Pharmacological targeting of ACSL4 with thiazolidinediones, a class of antidiabetic compound, ameliorated tissue demise in a mouse model of ferroptosis, suggesting that ACSL4 inhibition is a viable therapeutic approach to preventing ferroptosis-related diseases.
            • Record: found
            • Abstract: found
            • Article: not found

            Oxidized arachidonic and adrenic PEs navigate cells to ferroptosis.

            Enigmatic lipid peroxidation products have been claimed as the proximate executioners of ferroptosis-a specialized death program triggered by insufficiency of glutathione peroxidase 4 (GPX4). Using quantitative redox lipidomics, reverse genetics, bioinformatics and systems biology, we discovered that ferroptosis involves a highly organized oxygenation center, wherein oxidation in endoplasmic-reticulum-associated compartments occurs on only one class of phospholipids (phosphatidylethanolamines (PEs)) and is specific toward two fatty acyls-arachidonoyl (AA) and adrenoyl (AdA). Suppression of AA or AdA esterification into PE by genetic or pharmacological inhibition of acyl-CoA synthase 4 (ACSL4) acts as a specific antiferroptotic rescue pathway. Lipoxygenase (LOX) generates doubly and triply-oxygenated (15-hydroperoxy)-diacylated PE species, which act as death signals, and tocopherols and tocotrienols (vitamin E) suppress LOX and protect against ferroptosis, suggesting a homeostatic physiological role for vitamin E. This oxidative PE death pathway may also represent a target for drug discovery.
              • Record: found
              • Abstract: found
              • Article: not found

              RAS-RAF-MEK-dependent oxidative cell death involving voltage-dependent anion channels.

              Therapeutics that discriminate between the genetic makeup of normal cells and tumour cells are valuable for treating and understanding cancer. Small molecules with oncogene-selective lethality may reveal novel functions of oncoproteins and enable the creation of more selective drugs. Here we describe the mechanism of action of the selective anti-tumour agent erastin, involving the RAS-RAF-MEK signalling pathway functioning in cell proliferation, differentiation and survival. Erastin exhibits greater lethality in human tumour cells harbouring mutations in the oncogenes HRAS, KRAS or BRAF. Using affinity purification and mass spectrometry, we discovered that erastin acts through mitochondrial voltage-dependent anion channels (VDACs)--a novel target for anti-cancer drugs. We show that erastin treatment of cells harbouring oncogenic RAS causes the appearance of oxidative species and subsequent death through an oxidative, non-apoptotic mechanism. RNA-interference-mediated knockdown of VDAC2 or VDAC3 caused resistance to erastin, implicating these two VDAC isoforms in the mechanism of action of erastin. Moreover, using purified mitochondria expressing a single VDAC isoform, we found that erastin alters the permeability of the outer mitochondrial membrane. Finally, using a radiolabelled analogue and a filter-binding assay, we show that erastin binds directly to VDAC2. These results demonstrate that ligands to VDAC proteins can induce non-apoptotic cell death selectively in some tumour cells harbouring activating mutations in the RAS-RAF-MEK pathway.

                Author and article information

                Contributors
                junxiamin@zju.edu.cn
                fudiwang.lab@gmail.com , fwang@zju.edu.cn
                Journal
                Hepatology
                Hepatology
                10.1002/(ISSN)1527-3350
                HEP
                Hepatology (Baltimore, Md.)
                John Wiley and Sons Inc. (Hoboken )
                0270-9139
                1527-3350
                16 May 2017
                August 2017
                : 66
                : 2 ( doiID: 10.1002/hep.v66.2 )
                : 449-465
                Affiliations
                [ 1 ] School of Public Health, Zhengzhou University; School of Public Health, The First Affiliated Hospital, Institute of Translational Medicine, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases School of Medicine, Zhejiang University Hangzhou China
                [ 2 ] Department of Biochemistry and Molecular Biology, Program in Molecular and Cell Biology, School of Medicine Zhejiang University Hangzhou China
                Author notes
                [*] [* ] ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO:

                Fudi Wang, M.D., Ph.D.

                School of Public Health, Zhengzhou University

                School of Public Health, School of Medicine, Zhejiang University

                Hangzhou 310058, China

                E‐mail: fudiwang.lab@ 123456gmail.com or fwang@ 123456zju.edu.cn

                or

                Junxia Min, M.D., Ph.D.

                The First Affiliated Hospital, Institute of Translational Medicine

                School of Medicine, Zhejiang University

                Hangzhou, China

                E‐mail: junxiamin@ 123456zju.edu.cn

                Article
                HEP29117
                10.1002/hep.29117
                5573904
                28195347
                d9506495-b136-4bd2-9fef-6e6290919075
                © 2017 The Authors. H epatology published by Wiley Periodicals, Inc., on behalf of the American Association for the Study of Liver Diseases.

                This is an open access article under the terms of the Creative Commons Attribution‐NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.

                History
                : 25 November 2016
                : 09 February 2017
                Page count
                Figures: 7, Tables: 0, Pages: 17, Words: 7236
                Funding
                Funded by: National Natural Science Foundation of China
                Award ID: 31330036
                Award ID: 31530034
                Award ID: 31225013
                Award ID: 31570791
                Award ID: 91542205
                Award ID: 31500960
                Award ID: 31200892
                Award ID: 31401005
                Funded by: China Postdoctoral Science Foundation
                Award ID: 2016M601932
                Funded by: Zhejiang Provincial Natural Science Foundation of China
                Award ID: LZ15H160002
                Categories
                Original Article
                Original Articles
                Steatohepatitis/Metabolic Liver Disease
                Custom metadata
                2.0
                hep29117
                August 2017
                Converter:WILEY_ML3GV2_TO_NLMPMC version:5.1.8 mode:remove_FC converted:29.08.2017

                Gastroenterology & Hepatology
                Gastroenterology & Hepatology

                Comments

                Comment on this article

                Related Documents Log